Methotrexate Versus Triamcinilone Acetonide in Treatment of Recalcitrant Alopecia Areata
Alopecia Areata
About this trial
This is an interventional treatment trial for Alopecia Areata focused on measuring Alopecia areata, Methotrexate, Triamcinolone, microneedling
Eligibility Criteria
Inclusion Criteria: Age groups: > 12 years old. Sex: both sexes. Co-operative Patients. Recalcitrant or resistant cases to treatment (meaning that all patients had received various modalities of treatment in the past with poor/partial response or relapse after discontinuing therapy. Exclusion Criteria: Patients <12 years. Pregnant and lactating women. Patients with any underlying Systemic disorders. Patients with HBV or HCV. Patient with active infection of T.B. Patients with bone marrow suppression (leukopenia, thrombocytopenia) Patients who had received any other modalities of treatment in last 3-6 months.
Sites / Locations
- Al-Azhar University
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Group 1= Methotrexate
Group2=Triamcinilone
After microneedling, we will apply methotrexate topically (25 mg/ml) on half of the scalp at a dose of 0.02ml/cm2 with a maximum of 0.1-0.2 ml (2,5-5 mg) and rub it gently. The patient will take a session every 2 weeks for 12 weeks, on the same patient on the other patch or half of the scalp according to the pattern.
we will use Triamcinolone acetonide 40 mg/1ml after microneedking at dose 5mg/ml concentration;1/8/ 1:7 dilution session every 3 weeks for 12 weeks. then after 12 weeks of treatment we will follow up our patients after discontinuing therapy for other 12 weeks and evaluate.